BeOne Medicines AG ONC.OQ, ONC.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2025
The Basel Basel-stadt-based company is expected to report a 29.3% increase in revenue to $1.458 billion from $1.13 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for BeOne Medicines AG is for earnings of $1.21 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BeOne Medicines AG is $400.00, about 7.9% above its last closing price of $370.64
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | 0.76 | 0.86 | 1.09 | Beat | 27.5 |
Jun. 30 2025 | 0.07 | 0.11 | 0.84 | Beat | 696.2 |
Mar. 31 2025 | -0.88 | -0.72 | 0.01 | Beat | 101.4 |
Dec. 31 2024 | -0.98 | -0.89 | -1.43 | Missed | -60.9 |
Sep. 30 2024 | -1.17 | -1.02 | -1.15 | Missed | -12.9 |
Jun. 30 2024 | -2.10 | -2.15 | -1.15 | Beat | 46.5 |
Mar. 31 2024 | -2.96 | -2.93 | -2.41 | Beat | 17.7 |
Dec. 31 2023 | -3.24 | -3.96 | -3.53 | Beat | 10.8 |
This summary was machine generated February 24 at 08:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)